Cirrhosis/Liver Failure News

A novel liver dialysis device that rids the body of dysfunctional albumin and replaces it with fresh albumin significantly improved survival rates among patients with acute-on-chronic liver failure, according to a presenter at The International Liver Congress.

Independent risk factors for COVID-19 mortality included chronic liver disease and alcohol use disorders, which also contributed to disease burden in 2020, according to a presenter at the International Liver Congress.

Although pre-and post-COVID-19 monthly admission rates were stable for non-alcoholic and alcoholic cirrhosis; alcoholic hepatitis admissions increased, according to a presentation at the International Liver Congress.

In preparation for the International Liver Conference June 23-26, Healio Gastroenterology and Hepatology presents the following report on the latest stories in liver research.

Blood transfusion did not significantly improve the prognosis of patients with digestive bleeding by esophageal varices, according to a study in Open Access Journal of Gastroenterology.

Ultrasound quality changed between examinations for hepatocellular carcinoma detection in patients with cirrhosis, according to research published in Clinical Gastroenterology and Hepatology.

In an exclusive video, Ray Chung, MD, detailed abstracts presented by the American Association for Study of Liver Diseases presented during Digestive Disease Week.

Patients with cirrhosis had a higher abundance of beta-lactamase, vancomycin and quinolone genes in their gut microbiota compared with patients with inflammatory bowel disease, chronic kidney disease and diabetes, according to a presentation from Digestive Diseases Week.

Despite ongoing COVID-19 infection control restrictions, volumes of inpatient consults for alcohol-related gastrointestinal and liver diseases had significantly decreased at the onset of the COVID-19 pandemic, but quickly returned to normal levels, according to an expert presentation during a press conference in advance of Digestive Diseases Week.

Golexanolone was well tolerated and correlated with improvement in cognitive performance in patients with hepatic encephalopathy, according to a study published in the Journal of Hepatology.